<DOC>
	<DOC>NCT02762799</DOC>
	<brief_summary>BCD-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety of single-injection of Leucostim® to healthy volunteers compared to Neupogen®</brief_summary>
	<brief_title>Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®</brief_title>
	<detailed_description />
	<mesh_term>Leukocytosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Written informed consent. Male gender. Age between 18 and 45 years. Normal body mass index. Verified diagnosis "healthy", established according to the anamnesis, physical examination and laboratory findings. Absence of alcohol or drug abuse. History of use of filgrastim. Allergy to any components of study drugs. Acute hemorrhage, donation of blood / plasma or blood transfusions during last 2 months prior to enrollment in the study, history of chronic bleeding. Surgical interventions during last 30 days prior to screening or planed surgical intervention during the study. Any diseases that could interfere with pharmacokinetics of filgrastim, including chronic liver, liver or blood diseases, diseases of cardiovascular, lung and neuroendocrine systems. Fever with body temperature higher than 40°С.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>neutrophil count</keyword>
	<keyword>filgrastim</keyword>
	<keyword>granulocyte colony-stimulating factor</keyword>
</DOC>